Tyra Biosciences, INC 8-K filings

Tyra Biosciences announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Tyra Biosciences announced first quarter 2026 financial results, highlighting progress in its dabogratinib clinical programs and a strong cash position extending runway into late 2028.

Tyra Biosciences has expanded its board of directors to ten members with the appointment of biopharmaceutical veteran Habib J. Dable.

Tyra Biosciences has designated Julia Rueb as its new principal accounting officer, effective April 1, 2026.

Tyra Biosciences, Inc. announced it will issue and sell 4 million shares of common stock to a large investment firm, expecting $126 million in gross proceeds.

Tyra Biosciences announced its fourth quarter and full-year 2025 financial results, highlighting progress on its dabogratinib 3x3 strategy and a cash runway through at least 2027.

Tyra Biosciences, Inc. announced the appointment of Bhavesh Ashar as Chief Operating Officer and Daniel Bensen as Chief Discovery Officer, effective December 1, 2025.

Tyra Biosciences reported third-quarter 2025 financial results, highlighting clinical advancements for dabogratinib and a cash runway extending through at least 2027.

Tyra Biosciences announced the dosing of the first child in its Phase 2 clinical study of dabogratinib for achondroplasia, with initial results expected in late 2026.

Tyra Biosciences reports Q2 2025 financial results and significant progress across its clinical-stage precision medicine pipeline, including dosing the first patient in a Phase 2 bladder cancer study.

Tyra Biosciences, Inc. announced the dosing of the first patient in its Phase 2 clinical study (SURF302) for TYRA-300 in bladder cancer, while also updating the timeline for its pediatric achondroplasia study (BEACH301).

Tyra Biosciences, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent auditor during its 2025 Annual Meeting of Stockholders held on May 29, 2025.

Tyra Biosciences announces Q1 2025 financial results, highlighting clinical advancements in TYRA-300, TYRA-200, and TYRA-430 programs, with a cash runway through at least 2027.

Tyra Biosciences announces positive financial results for 2024, highlighting the clearance of three INDs by the FDA and a strong cash position extending into 2027.

Tyra Biosciences announces the appointment of Adele M. Gulfo to its Board of Directors and Compensation Committee, succeeding Nina Kjellson who resigned effective January 29, 2025.

Tyra Biosciences announced positive interim clinical results for TYRA-300 in metastatic urothelial cancer, along with other corporate updates including a strengthened leadership team and a strong cash position.

Tyra Biosciences has announced that the FDA has cleared its Investigational New Drug application for TYRA-300, allowing the company to proceed with a Phase 2 clinical trial for children with achondroplasia.

Tyra Biosciences reported positive interim clinical data for TYRA-300, showing significant anti-tumor activity and a favorable safety profile in patients with metastatic urothelial cancer.

Tyra Biosciences has entered into an agreement to exchange 3 million common shares for pre-funded warrants with Boxer Capital and RA Capital.

Tyra Biosciences announced its second quarter 2024 financial results, highlighting progress in its clinical programs and a strengthened board.

Tyra Biosciences' stockholders approved an amendment to the company's charter to limit officer liability at the 2024 Annual Meeting.

Tyra Biosciences announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position.

Tyra Biosciences has appointed Susan Moran and S. Michael Rothenberg as new independent directors, increasing the board size to ten members, effective May 7, 2024.

Tyra Biosciences announced its full year 2023 financial results, highlighted clinical advancements, and secured a $200 million private placement financing.

Tyra Biosciences has successfully raised approximately $200 million through a private placement to fund the clinical development of its drug candidates and other corporate activities.

Tyra Biosciences has been granted Rare Pediatric Disease Designation by the FDA for TYRA-300, an oral FGFR3 selective inhibitor, intended for the treatment of achondroplasia.